-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SYn9sY1PsWDmNFZ4NpGuhtayoa9lMVFxaDU9ui8VYNlIA4KWm+Uk9iahLWm2g8T8 qoM1Y4RrmUs7CITZgSJl+A== 0000878088-08-000012.txt : 20080115 0000878088-08-000012.hdr.sgml : 20080115 20080115164402 ACCESSION NUMBER: 0000878088-08-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080111 FILED AS OF DATE: 20080115 DATE AS OF CHANGE: 20080115 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PAR PHARMACEUTICAL COMPANIES, INC. CENTRAL INDEX KEY: 0000878088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223122182 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 BUSINESS PHONE: 201-802-4000 MAIL ADDRESS: STREET 1: 300 TICE BOULEVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 FORMER COMPANY: FORMER CONFORMED NAME: PHARMACEUTICAL RESOURCES INC DATE OF NAME CHANGE: 19940526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAUGHEY THOMAS CENTRAL INDEX KEY: 0001272247 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10827 FILM NUMBER: 08531547 MAIL ADDRESS: STREET 1: 300 TICE BOULDVARD CITY: WOODCLIFF LAKE STATE: NJ ZIP: 07677 4 1 primary_doc.xml PRIMARY DOCUMENT X0202 4 2008-01-11 0 0000878088 PAR PHARMACEUTICAL COMPANIES, INC. PRX 0001272247 HAUGHEY THOMAS C/O PAR PHARMACEUTICAL COMPANIES, INC. 300 TICE BOULDVARD WOODCLIFF LAKE NJ 07677 0 1 0 0 Exec VP, General Counsel Common Stock 2008-01-11 4 A 0 36849 0 A 132811 D Award of shares of Restricted Stock under the Company's 2004 Performance Equity Plan. 33% of the shares of Restricted Stock vest as follows: 25% vest on the first anniversary of the date of grant and an additional 25% vest on each anniversary thereafter until the 33% are fully vested; 67% of the shares of Restricted Stock vest as follows: over a three-year period, upon the achievement by the Company of defined goals of Total Returns to Shareholders relative to a defined peer group of pharmaceutical companies. The closing price of the Company's Common Stock as reported by The New York Stock Exchange, Inc. on the date of grant was $21.71. Includes all outstanding shares of Restricted Stock and Restricted Stock Units held by Mr. Haughey. /s/ Marian E. Gustafson for Thomas J. Haughey 2008-01-15 -----END PRIVACY-ENHANCED MESSAGE-----